Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Deferred Revenue (2023 - 2025)

Immunome's Current Deferred Revenue history spans 3 years, with the latest figure at $4.0 million for Q1 2025.

  • For Q1 2025, Current Deferred Revenue fell 68.5% year-over-year to $4.0 million; the TTM value through Mar 2025 reached $4.0 million, down 68.5%, while the annual FY2024 figure was $6.9 million, 56.57% down from the prior year.
  • Current Deferred Revenue reached $4.0 million in Q1 2025 per IMNM's latest filing, down from $6.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $27.6 million in Q1 2023 to a low of $4.0 million in Q1 2025.
  • Average Current Deferred Revenue over 3 years is $14.4 million, with a median of $12.7 million recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: tumbled 42.92% in 2024, then tumbled 68.5% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $16.0 million in 2023, then tumbled by 56.57% to $6.9 million in 2024, then tumbled by 42.16% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Current Deferred Revenue are $4.0 million (Q1 2025), $6.9 million (Q4 2024), and $9.7 million (Q3 2024).